Core Points - The company announced the results of the first vesting period of the 2024 restricted stock incentive plan, with a total of 6,302,998 shares vested [2][10]. Group 1: Stock Vesting Details - The shares vested are sourced from the company's repurchase of its own A-shares from the secondary market [3][9]. - A total of 203 individuals are involved in this vesting process [8]. - The company completed the share registration procedures on November 13, 2025, and received a confirmation from the China Securities Depository and Clearing Corporation [10]. Group 2: Decision-Making Process - The decision-making process for the incentive plan included multiple meetings of the board and supervisory committee, with relevant proposals approved on September 28, 2024, and subsequent meetings held to finalize details [4][5][6]. - The company conducted a self-examination regarding insider trading prior to the announcement of the incentive plan, finding no violations [5]. Group 3: Restrictions on Share Transfer - There are specific restrictions on the transfer of shares for directors and senior management, including limits on annual transfers and conditions for selling shares within six months of purchase [8].

（文章来源：证券日报） 证券日报网讯 11月14日晚间，金盘科技发布公告称，公司于2025年11月14日召开第三届董事会第二十 九次会议，审议通过了《关于向2025年限制性股票激励计划激励对象首次授予限制性股票的议案》，同 意并确定公司本次激励计划首次授予日为2025年11月14日，向符合授予条件的391名激励对象首次授予 400.00万股限制性股票，授予价格为45.89元/股。 ...

每经AI快讯，今天国际（SZ 300532，收盘价：12.35元）11月14日晚间发布公告称，公司第五届第二十 次董事会会议于2025年11月14日以通讯表决方式召开。会议审议了《关于作废2021年限制性股票激励计 划部分已授予尚未归属的限制性股票的议案》等文件。 截至发稿，今天国际市值为56亿元。 每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 （记者 王晓波） 2025年1至6月份，今天国际的营业收入构成为：加工制造业占比98.6%，其他业务占比1.4%。 ...

格隆汇11月14日丨金盘科技(688676.SH)公布，公司于2025年11月14日召开第三届董事会第二十九次会 议，审议通过了《关于向2025年限制性股票激励计划激励对象首次授予限制性股票的议案》，同意并确 定公司本次激励计划首次授予日为2025年11月14日，向符合授予条件的391名激励对象首次授予400.00 万股限制性股票，授予价格为45.89元/股。 ...

金盘科技公告称，公司实施限制性股票激励计划，拟授予权益总计500万股，占当前公司总股本的 1.087%。其中，首次授予400万股，占比80%，涉及董事、高管、核心技术人员、中层管理人员及核心 业务骨干等；预留100万股，占比20%。激励对象包括轮值总裁杨霞玲获授15万股、高级副总裁栗记涛 等多人获授不同数量股票。预留部分激励对象将在计划经股东会审议通过后12个月内确定，超期未明确 则预留权益失效。 ...

Group 1 - The core point of the article is that DiAo Micro (SH 688381) announced the convening of its 20th meeting of the second board of directors on November 14, 2025, to review the proposal for adjusting the grant price of the 2024 restricted stock incentive plan [1] - For the year 2024, DiAo Micro's revenue composition is entirely from integrated circuits, accounting for 100.0% [1] - As of the time of reporting, DiAo Micro has a market capitalization of 5.9 billion yuan [1]

Core Viewpoint - The company has completed the registration of the 2025 restricted stock incentive plan, with specific details regarding the grant date, number of shares, and pricing outlined in the announcement [2][5][12]. Group 1: Incentive Plan Details - The grant date for the deferred portion of the restricted stock is set for October 24, 2025 [2]. - The listing date for the deferred restricted stock is November 20, 2025 [16]. - A total of 232,800 shares will be granted to 2 individuals at a price of 8.11 yuan per share [2][12][13]. Group 2: Approval Process - The incentive plan has undergone various approval processes, including meetings of the board and supervisory committee, with no objections raised during the internal publicity period [3][4]. - The plan was approved at the 2024 annual general meeting held on May 20, 2025 [4]. Group 3: Performance Assessment - The performance assessment for the incentive plan will be based on net profit and vehicle display revenue for the years 2025 to 2027 [7][8]. - If the company fails to meet the performance targets, the unvested shares will be repurchased by the company [8]. Group 4: Financial Impact - The total share capital will increase from 223,432,221 shares to 223,665,021 shares, resulting in a diluted earnings per share of 0.53 yuan for 2024 [20]. - The funds raised from the stock grant will be used to supplement working capital [18]. Group 5: Compliance and Control - The stock grant will not affect the company's compliance with listing conditions or change the control of the company [21]. - The company has ensured that the stock grant does not lead to any changes in the distribution of equity [21].

Core Viewpoint - Jiangsu Maxinlin Aviation Technology Co., Ltd. has announced the results of the first vesting period of its 2024 restricted stock incentive plan, with 1,425,000 shares set to be listed on November 18, 2025 [2][4]. Summary by Sections Stock Listing and Incentive Plan - The stock listing type is for equity incentive shares, with a total of 1,425,000 shares to be listed [2][3]. - The shares will be available for trading starting November 18, 2025 [4]. Decision-Making Process and Disclosure - On August 28, 2024, the company held a board meeting to approve the incentive plan and its management measures [6]. - The company conducted a public announcement regarding the independent directors' solicitation of voting rights on August 29, 2024 [5]. - The names and positions of the incentive plan participants were publicly disclosed from August 29 to September 7, 2024, with no objections received [5]. Vesting Details - A total of 24 individuals will benefit from the stock vesting, as one participant lost eligibility due to resignation [8]. - The shares are sourced from the company's A-share common stock issued to the incentive participants [8]. Capital Changes and Financial Impact - Following the vesting, the company's total share capital will increase from 145,426,667 shares to 146,851,667 shares [9]. - The new shares represent approximately 0.98% of the total shares before vesting, which will dilute the earnings per share but will not significantly impact the company's financial status [11]. Verification and Registration - The verification report by Lianda Accounting Firm confirmed that the company received a total of RMB 18,525,000 from the 24 participants, with RMB 1,425,000 as registered capital [10]. - The share registration procedures were completed on November 12, 2025 [10].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600216 证券简称：浙江医药 公告编号：2025-043 浙江医药股份有限公司关于2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 浙江医药股份有限公司（以下简称"公司"）于2025年10月27日召开第十届八次董事会会议，审议通过了 《关于〈浙江医药股份有限公司2025年限制性股票激励计划（草案）〉及其摘要的议案》等关于公司 2025年限制性股票激励计划（以下简称"本激励计划"）的相关议案，并于2025年10月28日在上海证券交 易所网站（www.sse.com.cn）披露了相关公告。 根据《上市公司股权激励管理办法》《上市公司信息披露管理办法》等有关法律、法规、部门规章、规 范性文件以及公司相关管理制度的规定，公司对本激励计划采取了充分必要的保密措施，并对本激励计 划的内幕信息知情人进行了登记。根据《上市公司股权激励管理办法》，公司通过中国证券登记结算有 限责任公司上海分公司（以下简称"中登公司 ...

Core Viewpoint - The company has announced the verification and public disclosure of the list of incentive recipients for its 2025 restricted stock incentive plan, ensuring compliance with relevant regulations and internal procedures [1][7]. Group 1: Public Disclosure and Verification Process - The company disclosed the draft of the 2025 restricted stock incentive plan and related documents on October 28, 2025, on the Shanghai Stock Exchange website [1][9]. - The public disclosure included the names and positions of the proposed incentive recipients, with a public notice period from October 31 to November 10, 2025, lasting no less than 10 days [1][9]. - Feedback from employees was collected during the public notice period, with one inquiry received and resolved, confirming no objections from other employees [1][9]. Group 2: Verification by Supervisory Board - The supervisory board verified the list of proposed incentive recipients, ensuring they met the criteria set forth in the management regulations and stock exchange rules [3][5]. - The proposed recipients do not fall under any disqualifying conditions as outlined in the management regulations, such as being deemed inappropriate candidates by regulatory bodies within the last 12 months [4][10]. - The recipients are identified as core personnel and others deemed necessary for motivation, excluding directors, supervisors, senior management, and significant shareholders [4][11]. Group 3: Verification by Compensation and Assessment Committee - The compensation and assessment committee conducted a similar verification process, confirming the legitimacy of the proposed recipients' qualifications [7][10]. - The committee also found that the proposed recipients met all necessary conditions and did not include any disqualified individuals as per the management regulations [10][12]. - The committee concluded that the proposed recipients' qualifications are valid and comply with all relevant laws and regulations [11][12].